Avenue Therapeutics Reports Full Year 2018 Financial Results and Recent Corporate Highlights

Ads

You May Also Like

Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon PTH as Treatment for Hypoparathyroidism

COPENHAGEN, Denmark, June 06, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical ...

Cellectar Biosciences Announces $2 Million NCI SBIR Contract for a Phase 2 Clinical Study

MADISON, Wis., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) ("the company"), ...